Jessica M. Stempel on Aza-Ven +/- Pembro in older AML
Amer Zeidan, Associate Professor of Medicine at Yale University, shared a post on X:
“Dr. Jessica M. Stempel fantastically presented our investigator-initiated randomized phase 2 trial of aza-ven +/- Pembro in older AMLsm, ASH24 which was unfortunately negative but showed importance of using ELN2024 for risk stratification and feasibility of central MRD in primary endpoint. IMG.”
Amer Zeidan is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid Malignancies DART (Disease Aligned Research Team), and the director of Continuing Medical Education (CME) at the Hematology division and chairs the Protocol Review Committee (PRC) at Yale Cancer Center. Dr. Zeidan is a well-known leukemia researcher with a special focus on targeted therapies and immunotherapy for myeloid malignancies, and a social media influencer in the field of blood cancer.
More posts featuring Amer Zeidan.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023